ADYX Stock Overview
A clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Adynxx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | -99.00% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.99% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ADYX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -99.0% | 4.3% | 1.6% |
| 1Y | n/a | 18.8% | 32.3% |
Return vs Industry: Insufficient data to determine how ADYX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ADYX performed against the US Market.
Price Volatility
| ADYX volatility | |
|---|---|
| ADYX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADYX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ADYX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Rick Orr | www.adynxx.com |
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Adynxx, Inc. Fundamentals Summary
| ADYX fundamental statistics | |
|---|---|
| Market cap | US$5.00 |
| Earnings (TTM) | -US$10.51m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ADYX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADYX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.51m |
| Earnings | -US$10.51m |
Last Reported Earnings
Sep 30, 2019
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ADYX perform over the long term?
See historical performance and comparison